Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-868 in Overweight and Obese Adults With Type 1 Diabetes Mellitus
NCT06062069Phase 2Completed
- Sponsor
- Carmot Therapeutics
- Start
- Nov 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of acmopatide in type 1 diabetes mellitus (T1D), obesity and Overweight (4 arms), sponsored by Carmot Therapeutics. Primary endpoint: Change From Baseline in Glycated Hemoglobin at 16 weeks. Started Nov 2023; status: completed.
02
Drugs
acmopatide
03
Conditions
type 1 diabetes mellitus (T1D)obesityOverweight
Beyond the preview
Go deeper on NCT06062069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06062069.